CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy

Leyuan Ma, Jeffrey I. Boucher, Janet Paulsen, Sebastian Matuszewski, Christopher A. Eide, Jianhong Ou, Garrett Eickelberg, Richard Press, Lihua Julie Zhu, Brian Druker, Susan Branford, Scot A. Wolfe, Jeffrey D. Jensen, Celia A. Schiffer, Michael R. Green, Daniel N. Bolon

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Developing tools to accurately predict the clinical prevalence of drug-resistant mutations is a key step toward generating more effective therapeutics. Here we describe a high-throughput CRISPR-Cas9–based saturated mutagenesis approach to generate comprehensive libraries of point mutations at a defined genomic location and systematically study their effect on cell growth. As proof of concept, we mutagenized a selected region within the leukemic oncogene BCR-ABL1. Using bulk competitions with a deep-sequencing readout, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of mutations on growth in the presence or absence of drug were critical for predicting clinically relevant resistant mutations, many of which were cancer adaptive in the absence of drug pressure. Using this approach, we identified all clinically isolated BCR-ABL1 mutations and achieved a prediction score that correlated highly with their clinical prevalence. The strategy described here can be broadly applied to a variety of oncogenes to predict patient mutations and evaluate resistance susceptibility in the development of new therapeutics.

Original languageEnglish (US)
Pages (from-to)11751-11756
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number44
DOIs
StatePublished - Oct 31 2017

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Drug Resistance
Mutagenesis
Mutation
Oncogenes
Pharmaceutical Preparations
High-Throughput Nucleotide Sequencing
Growth
Point Mutation
Libraries
Pressure
Therapeutics

Keywords

  • BCR-ABL
  • CRISPR-Cas9–based genome editing
  • Drug resistance
  • Saturated mutagenesis
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • General

Cite this

CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. / Ma, Leyuan; Boucher, Jeffrey I.; Paulsen, Janet; Matuszewski, Sebastian; Eide, Christopher A.; Ou, Jianhong; Eickelberg, Garrett; Press, Richard; Zhu, Lihua Julie; Druker, Brian; Branford, Susan; Wolfe, Scot A.; Jensen, Jeffrey D.; Schiffer, Celia A.; Green, Michael R.; Bolon, Daniel N.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 44, 31.10.2017, p. 11751-11756.

Research output: Contribution to journalArticle

Ma, L, Boucher, JI, Paulsen, J, Matuszewski, S, Eide, CA, Ou, J, Eickelberg, G, Press, R, Zhu, LJ, Druker, B, Branford, S, Wolfe, SA, Jensen, JD, Schiffer, CA, Green, MR & Bolon, DN 2017, 'CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 44, pp. 11751-11756. https://doi.org/10.1073/pnas.1708268114
Ma, Leyuan ; Boucher, Jeffrey I. ; Paulsen, Janet ; Matuszewski, Sebastian ; Eide, Christopher A. ; Ou, Jianhong ; Eickelberg, Garrett ; Press, Richard ; Zhu, Lihua Julie ; Druker, Brian ; Branford, Susan ; Wolfe, Scot A. ; Jensen, Jeffrey D. ; Schiffer, Celia A. ; Green, Michael R. ; Bolon, Daniel N. / CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 44. pp. 11751-11756.
@article{cabd3fd99fba4d1ea812b70571f63514,
title = "CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy",
abstract = "Developing tools to accurately predict the clinical prevalence of drug-resistant mutations is a key step toward generating more effective therapeutics. Here we describe a high-throughput CRISPR-Cas9–based saturated mutagenesis approach to generate comprehensive libraries of point mutations at a defined genomic location and systematically study their effect on cell growth. As proof of concept, we mutagenized a selected region within the leukemic oncogene BCR-ABL1. Using bulk competitions with a deep-sequencing readout, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of mutations on growth in the presence or absence of drug were critical for predicting clinically relevant resistant mutations, many of which were cancer adaptive in the absence of drug pressure. Using this approach, we identified all clinically isolated BCR-ABL1 mutations and achieved a prediction score that correlated highly with their clinical prevalence. The strategy described here can be broadly applied to a variety of oncogenes to predict patient mutations and evaluate resistance susceptibility in the development of new therapeutics.",
keywords = "BCR-ABL, CRISPR-Cas9–based genome editing, Drug resistance, Saturated mutagenesis, Tyrosine kinase inhibitors",
author = "Leyuan Ma and Boucher, {Jeffrey I.} and Janet Paulsen and Sebastian Matuszewski and Eide, {Christopher A.} and Jianhong Ou and Garrett Eickelberg and Richard Press and Zhu, {Lihua Julie} and Brian Druker and Susan Branford and Wolfe, {Scot A.} and Jensen, {Jeffrey D.} and Schiffer, {Celia A.} and Green, {Michael R.} and Bolon, {Daniel N.}",
year = "2017",
month = "10",
day = "31",
doi = "10.1073/pnas.1708268114",
language = "English (US)",
volume = "114",
pages = "11751--11756",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "44",

}

TY - JOUR

T1 - CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy

AU - Ma, Leyuan

AU - Boucher, Jeffrey I.

AU - Paulsen, Janet

AU - Matuszewski, Sebastian

AU - Eide, Christopher A.

AU - Ou, Jianhong

AU - Eickelberg, Garrett

AU - Press, Richard

AU - Zhu, Lihua Julie

AU - Druker, Brian

AU - Branford, Susan

AU - Wolfe, Scot A.

AU - Jensen, Jeffrey D.

AU - Schiffer, Celia A.

AU - Green, Michael R.

AU - Bolon, Daniel N.

PY - 2017/10/31

Y1 - 2017/10/31

N2 - Developing tools to accurately predict the clinical prevalence of drug-resistant mutations is a key step toward generating more effective therapeutics. Here we describe a high-throughput CRISPR-Cas9–based saturated mutagenesis approach to generate comprehensive libraries of point mutations at a defined genomic location and systematically study their effect on cell growth. As proof of concept, we mutagenized a selected region within the leukemic oncogene BCR-ABL1. Using bulk competitions with a deep-sequencing readout, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of mutations on growth in the presence or absence of drug were critical for predicting clinically relevant resistant mutations, many of which were cancer adaptive in the absence of drug pressure. Using this approach, we identified all clinically isolated BCR-ABL1 mutations and achieved a prediction score that correlated highly with their clinical prevalence. The strategy described here can be broadly applied to a variety of oncogenes to predict patient mutations and evaluate resistance susceptibility in the development of new therapeutics.

AB - Developing tools to accurately predict the clinical prevalence of drug-resistant mutations is a key step toward generating more effective therapeutics. Here we describe a high-throughput CRISPR-Cas9–based saturated mutagenesis approach to generate comprehensive libraries of point mutations at a defined genomic location and systematically study their effect on cell growth. As proof of concept, we mutagenized a selected region within the leukemic oncogene BCR-ABL1. Using bulk competitions with a deep-sequencing readout, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of mutations on growth in the presence or absence of drug were critical for predicting clinically relevant resistant mutations, many of which were cancer adaptive in the absence of drug pressure. Using this approach, we identified all clinically isolated BCR-ABL1 mutations and achieved a prediction score that correlated highly with their clinical prevalence. The strategy described here can be broadly applied to a variety of oncogenes to predict patient mutations and evaluate resistance susceptibility in the development of new therapeutics.

KW - BCR-ABL

KW - CRISPR-Cas9–based genome editing

KW - Drug resistance

KW - Saturated mutagenesis

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85032661256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032661256&partnerID=8YFLogxK

U2 - 10.1073/pnas.1708268114

DO - 10.1073/pnas.1708268114

M3 - Article

C2 - 29078326

AN - SCOPUS:85032661256

VL - 114

SP - 11751

EP - 11756

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 44

ER -